Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).

Date publication

octobre 2019

Journal

The oncologist

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier , Dr VERNEREY Dewi , Pr MANFREDI Sylvain , Mme HENRIQUES Julie

Tous les auteurs :
Palmieri LJ, Mineur L, Tougeron D, Rousseau B, Granger V, Gornet JM, Smith D, Lievre A, Galais MP, Doat S, Pernot S, Bignon-Bretagne AL, Metges JP, Baba-Hamed N, Michel P, Obled S, Vitellius C, Bouche O, Saban-Roche L, Buecher B, des Guetz G, Locher C, Trouilloud I, Goujon G, Dior M, Manfredi S, Soularue E, Phelip JM, Henriques J, Vernery D, Coriat R

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31578276

Résumé

Patients with wild-type (WT) nonresectable metastatic colorectal cancer (mCRC) may receive either bevacizumab or an anti-epidermal growth factor receptor (EGFR) combined with first-line, 5-fluorouracil-based chemotherapy. Without the status information, the oncologist can either start chemotherapy with bevacizumab or wait for the introduction of the anti-EGFR. Our objective was to compare both strategies in a routine practice setting.

Mots clés

Anti‐epidermal growth factor receptor, Bevacizumab, Metastatic colorectal cancer, RAS status

Référence

Oncologist. 2019 Oct 2;: